Morning Dew on Foxglove
A group of medicines extracted from foxglove plants are called Digitalin. The use of Digitalis purpurea extract containing cardiac glycosides for the treatment of heart conditions was first described in the English speaking medical literature by William Withering, in 1785,[10] which is considered the beginning of modern therapeutics.[11][12]It is used to increase cardiac contractility (it is a positive inotrope) and as an antiarrhythmic agent to control the heart rate, particularly in the irregular (and often fast) atrial fibrillation. Digitalis is hence often prescribed for patients in atrial fibrillation, especially if they have been diagnosed with congestive heart failure. Digoxin was approved for heart failure in 1998 under current regulations by the Food and Drug Administration on the basis of prospective randomized study and clinical trials. It was also approved for the control of ventricular response rate for patients with atrial fibrillation. Recent American College of Cardiology/American Heart Association guidelines recommend digoxin for symptomatic chronic heart failure for patients with reduced systolic function, preservation of systolic function, and/or rate control for atrial fibrillation with a rapid ventricular response. Recent Heart Failure Society of America guidelines for heart failure provide similar recommendations. Despite its relatively recent approval by the Food and Drug Administration and the guideline recommendations, digoxin use is decreasing in patients with heart failure. This is likely the result of several factors. Digoxin has not been promoted by the pharmaceutical industry and has received little attention at national and international meetings, possibly the result of the development and promotion of other, newly patented therapies for heart failure. Also, safety concerns about digoxin therapy–increased mortality in women also may have contributed to this decrease in its use. Source: en.wikipedia.org/wiki/Digitalis
Morning Dew on Foxglove
A group of medicines extracted from foxglove plants are called Digitalin. The use of Digitalis purpurea extract containing cardiac glycosides for the treatment of heart conditions was first described in the English speaking medical literature by William Withering, in 1785,[10] which is considered the beginning of modern therapeutics.[11][12]It is used to increase cardiac contractility (it is a positive inotrope) and as an antiarrhythmic agent to control the heart rate, particularly in the irregular (and often fast) atrial fibrillation. Digitalis is hence often prescribed for patients in atrial fibrillation, especially if they have been diagnosed with congestive heart failure. Digoxin was approved for heart failure in 1998 under current regulations by the Food and Drug Administration on the basis of prospective randomized study and clinical trials. It was also approved for the control of ventricular response rate for patients with atrial fibrillation. Recent American College of Cardiology/American Heart Association guidelines recommend digoxin for symptomatic chronic heart failure for patients with reduced systolic function, preservation of systolic function, and/or rate control for atrial fibrillation with a rapid ventricular response. Recent Heart Failure Society of America guidelines for heart failure provide similar recommendations. Despite its relatively recent approval by the Food and Drug Administration and the guideline recommendations, digoxin use is decreasing in patients with heart failure. This is likely the result of several factors. Digoxin has not been promoted by the pharmaceutical industry and has received little attention at national and international meetings, possibly the result of the development and promotion of other, newly patented therapies for heart failure. Also, safety concerns about digoxin therapy–increased mortality in women also may have contributed to this decrease in its use. Source: en.wikipedia.org/wiki/Digitalis